ClinicalTrials.gg
RecruitingNCT05751798Updated Jun 4, 2026

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

A Phase 1/2 interventional study of Part A: OSE-279 100mg and Part A: OSE-279 300mg in Solid Advanced Tumor, Lymphoma and NSCLC (Non-small Cell Lung Cancer), sponsored by OSE Immunotherapeutics. Recruiting at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by OSE Immunotherapeutics · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 237 studies in Lymphoma with a site in France — 33 open to participants now, 54 under way, 11 of them phase 3. Lymphoma · France.

Planned enrollment
158th of 199
41 · median 110
Started
2022
with 12 others
Phase 1/2
27 of 237
9 open now
Primary completion
2029-12
later than 45 of 53 live
Registered
216th of 237
by date

Among the 237 studies in Lymphoma with a site in France, this one is the 158th largest by planned enrollment of the 199 interventional ones that give a count, is one of 13 that started in 2022, is one of 27 in phase 1/2, reaches primary completion later than 45 of the 53 other live ones, and was the 216th registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

33 of the 237 studies in Lymphoma with a site in France are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 237 studies in Lymphoma with a site in France, or all of them as a file.
02

Study summary

This is a phase 1/2, multicenter, dose-finding and dose expansion study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas.

Read the detailed description
  • The PART A objectives are to determine the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Doses (RP2D) when administered as single IV infusion on every 3 or 6 weeks.
  • The PART B objective is to evaluate the safety of the combination of OSE-279 administered at the RP2D (600mg Q6W) and OSE2101 at the therapeutic dose as 1st line treatment of metastatic (stage IV) NSCLC.
  • The PART C objective is to assess the antitumor activity of OSE-279 in combination with OSE2101 versus 0SE-279 in terms of overall response rate (ORR) as assessed locally, in patients with 1st line metastatic (stage IV) NSCLC.
03

Conditions studied

  • Solid Advanced Tumor
  • Lymphoma
  • NSCLC (Non-small Cell Lung Cancer)

Keywords

  • Solid advanced tumor
  • Lymphoma
  • Rare tumor
  • PD-L1 positive tumor
  • PD-1 blocking monoclonal antibody
  • NSCLC (non-small cell lung cancer)
  • Cancer vaccine
  • Immune check point inhibitor
  • TEDOPI
  • OSE2101
  • OSE-2101
  • OSE 2101
  • OSE-279
  • OSE 279
  • HLA-A2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Parts B and C - INCLUSION CRITERIA

  1. Male or female, aged ≥ 18 years
  2. Signed and dated form (ICF) prior to any trialspecific procedures.
  3. performance status 0-1
  4. Patients must be affiliated to a social security system or an equivalent system, if applicable as per local regulations.
  5. Patients expressing HLA-A2 phenotype on blood sample performed by an experienced laboratory using a validated test (PCR or NGS). Additional patients HLA-A2 negative will be included in PART C.
  6. Tumor type: a) or cytologically documented Stage IV squamous or non-squamous NSCLC not eligible for definite surgery or radiation, without EGFR sensitizing mutation or ALK and ROS1 gene alterations eligible for targeted therapy or other mutations for which an approved therapy exists in (see protocol); b) expression by TPS ≥ 50% (local)
  7. Patients with NO prior systemic therapy including immunotherapy in the first-line metastatic setting. In case of /adjuvant therapy, therapy was completed at least 6 months prior to the diagnosis of metastatic disease.
  8. Patients with at least one according to v1.1.
  9. Adequate organ function:

    1. Bone marrow: neutrophils ≥ 1.5 x 109/L, ≥ 90 g/L, ≥ 100 x 109/L
    2. Renal function: serum creatinine ≤ 1.5 or CKDEPI ≥ 30 mL/min
    3. Liver function: and ALT ≤ 3 ULN, ≤ 1.5 ULN. In case of liver metastasis: AST and ALT ≤ 5 ULN. For patients with Gilbert's syndrome total bilirubin ≤ 3 ULN or direct bilirubin ≤ 1.5 ULN.

Parts B and C - NON-INCLUSION CRITERIA

  1. Patient eligible to surgical resection or another approved therapeutic regimen known to provide clinical benefit; Known to the active substances or to any of the of OSE2101 or docetaxel.
  2. Patient previously treated with approved/ anti-PD-1/PD-L1
  3. Patient with active disease or a documented history of autoimmune disease requiring systemic treatment (i.e., or drugs); see exceptions in protocol
  4. Patient participating in another clinical trial with a medicinal product
  5. Patients who have not recovered from AEs (i.e. > G1 according to v5.0) due to prior treatment with anti-cancer agents with exception of G2 neuropathy or any Grade alopecia. (see protocol)
  6. Patients with known additional progressing or requiring active treatment. Basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer are not non-inclusion criteria
  7. Patients with known active central nervous system metastases and/or carcinomatous meningitis. Patients with previously treated may participate provided they are stable (without evidence of progression by imaging for at least 4 weeks prior to C1D1 and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids (at doses > 10 mg/day methylprednisolone or equivalent) for 4 weeks prior C1D1
  8. Patients with active or history of non-infectious pneumonitis requiring steroids, or interstitial lung disease
  9. Patients with a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the duration of the study
  10. Patients with a history of uncontrolled or symptomatic, cardiovascular disease: stroke, myocardial infarction, angina pectoris, arrhythmias, congestive heart failure ( Class >2), or myocarditis within 6 months prior to first study drug administration
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
41 participants (estimated)

Study arms

  • Experimental
    Part A: OSE-279 100 mg

    Part A: Dose Level 1: OSE-279 100 mg

    Drug: Part A: OSE-279 100mg

  • Experimental
    Part A: OSE-279 300 mg

    Part A: Dose Level 2: OSE-279 300 mg

    Drug: Part A: OSE-279 300mg

  • Experimental
    Part A: OSE-279 600 mg

    Part A: Dose Level 3: OSE-279 600 mg

    Drug: Part A: OSE-279 600mg

  • Experimental
    Part B: OSE-279 600 mg and OSE2101

    Part B: OSE-279 600 mg and OSE2101

    Drug: Part B: OSE-279 600 mg and OSE2101

  • Experimental
    Drug: Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positif

    Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive

    Drug: Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive

  • Experimental
    Part C: OSE-279 600 mg - HLA-A2 positif

    Part C: OSE-279 600 mg - HLA-A2 positif

    Drug: Part C: OSE-279 600 mg - HLA-A2 positif

  • Experimental
    Part C: OSE-279 600 mg - HLA-A2 negative

    Part C: OSE-279 600 mg - HLA-A2 negative

    Drug: Part C: OSE-279 600 mg - HLA-A2 negative

Interventions

  • DrugPart A: OSE-279 100mg

    Human IgG4 mAb against PD-1

  • DrugPart A: OSE-279 300mg

    Human IgG4 mAb against PD-1

  • DrugPart A: OSE-279 600mg

    Human IgG4 mAb against PD-1

  • DrugPart B: OSE-279 600 mg and OSE2101

    OSE-279: OSE-279: Human IgG4 mAb against PD-1 OSE2101: Cancer vaccine

  • DrugPart C: OSE-279 600 mg and OSE2101 - HLA-A2 positive

    OSE-279: Human IgG4 mAb against PD-1 OSE2101: Cancer vaccine

  • DrugPart C: OSE-279 600 mg - HLA-A2 positif

    OSE-279: Human IgG4 mAb against PD-1

  • DrugPart C: OSE-279 600 mg - HLA-A2 negative

    OSE-279: Human IgG4 mAb against PD-1

06

What researchers measure

Primary outcomes

  1. Part A: Occurrence of dose limiting toxicity (DLT). Part B: Safety and tolerability of the combination OSE-279/OSE2101. Part C: Overall response rate (ORR) of the combination OSE-279/OSE2101

    Part A: Occurrence of dose limiting toxicity (DLT) Part B: Occurrence of dose limiting toxicity (DLT) Part C: ORR: Complete Response (CR) and Partial Response (PR) rate

    Time frame: Part A: DLT observation period is defined as the first 21 days after receiving the 1st injection of OSE-279 (Cycle 1) Part B: DLT observation period is defined as the first 6 weeks after receiving the combinaison Part C: Best response

Secondary outcomes

  1. Part A: Objective Response Rate (ORR). Part B: Complete Response (CR) and Partial Response (PR) rate. Part C: CR, PR and Stable Disease (SD) rate

    Part A: Objective Response Rate (ORR): complete response (CR) and partial response (PR), based on RECIST 1.1/RECIL and iRECIST Part B: Objective Response Rate (ORR): complete response (CR) and partial response (PR), based on RECIST 1.1/RECIL and iRECIST Part C: CR, PR and Stable Disease (SD) rate, based on RECIST 1.1/RECIL and iRECIST

    Time frame: Part A: Through study completion, an average of 1 year Part B: ORR, DCR, DOR, TTR, DCR at 12 weeks and 24 weeks, PFS, OS and OS at 12 months Part C: DCR,TTR, DOR, PFS at 12 weeks and 24 weeks, OS and OS rate at 12 months

  2. Part A and Part B: Disease Control Rate (DCR: CR, PR and SD). Part C: Time to response

    Part A and Part B: Disease Control Rate (DCR): complete response (CR), partial response (PR) and stable disease (SD) based on RECIST 1.1/RECIL and iRECIST

    Time frame: Part A: Through study completion, an average of 1 year

  3. Part A and Part B: Time to response. Part C: Duration of Objective Response (DOR)

    Part A and Part B: Time to response

    Time frame: Time

  4. Part A and Part B: Duration of response (DR). Part C: Progression Free Survival (PFS)

    Part A and Part B: Duration of response (DR). Part C: Progression Free Survival (PFS)

    Time frame: Part A: From the first assessment of CR or PR until the date of the first occurrence of PD, or until the date of death (up to 1 year)

  5. Part A and Part B: Progression Free Survival (PFS). Part C: DCR (CR+PR+SD) at 12 weeks and 24 weeks

    Part A and Part B: Progression Free Survival (PFS). Part C: DCR at 12 weeks and 24 weeks

    Time frame: Part A: From start of treatment until date of progression based on RECIST 1.1/RECIL and iRECIST or date of death (up to 1 year). Part C: DCR at 12 weeks and 24 weeks

  6. Part A: DCR at 12 weeks (CR+PR+SD). Part B: DCR at 12 weeks and 24 weeks (CR+PR+SD). Part C: Overall Survival (OS)

    Part A: DCR at 12 weeks (CR+PR+SD). Part B: DCR at 12 weeks and 24 weeks (CR+PR+SD). Part C: Overall Survival.

    Time frame: Part A: Up to 12 weeks Part B: at 12 weeks and 24 weeks

  7. Part A and Part B: Overall Survival (OS). Part C: Overall Survival (OS) rate.

    Part A and Part B: Overall Survival (OS). Part C: Overall Survival (OS) rate.

    Time frame: Part A and Part C: From start of treatment to Death (up to 2 years). Part C: Overall Survival (OS) rate at 12 months.

  8. Part B: Overall Survival (OS) rate.

    Time frame: Part B: Overall Survival (OS) rate at 12months

07

Study locations

10 of 11 sites recruiting
08

References and documents

Publications

  • Robert M, Kotecki N, Gomez-Roca C, Massard C, Postel-Vinay S, Raimbourg J, Brandao M, Korakis I, Rouge TM, Comis S, Imadalou K, Chevalier C, Cordonnier L, Josse C, Teppaz G, Seite M, Durand J, Thepenier V, Mary C, Gauttier V, Derame M, Morello A, Poirier N, Cassier PA. A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours. Eur J Cancer. 2026 Jun 3;240:116729. doi: 10.1016/j.ejca.2026.116729. Epub 2026 Apr 9. PubMed 42034003 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2029, 84 months after the start.

Of 66 industry-sponsored phase 1/2 interventional studies under Lymphoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 87. This study's planned 84 months is above that.

Counting every sponsor, half of 143 studies reached it within 74 months; a quarter within 48 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2023
First posted
Mar 2, 2023
StartActual
Dec 20, 2022
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05751798
Lead sponsor
OSE Immunotherapeutics
Responsible party
Sponsor
First posted
Mar 2, 2023
Start date
Dec 20, 2022
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Jun 4, 2026

Study contacts

Sylvie Jouve, PhD
Contact
sylvie.jouve@ose-immuno.com
+33 631 654 710
Silvia Comis, MD
Contact
silvia.comis@ose-immuno.com
+349 347 1495656

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion